- Home
- XAIR vs INAB Comparison
XAIR vs INAB Comparison
Compare XAIR & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | INAB |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 10.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | XAIR | INAB |
|---|---|---|
| Price | $0.94 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $11.00 | ★ $108.00 |
| AVG Volume (30 Days) | ★ 118.3K | 56.6K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,802,000.00 | N/A |
| Revenue This Year | $128.45 | N/A |
| Revenue Next Year | $153.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $0.90 | $1.32 |
| 52 Week High | $11.20 | $12.53 |
Technical Indicators
Market Signals| Indicator | XAIR | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 28.95 | 26.17 |
| Support Level | $0.91 | $1.73 |
| Resistance Level | $1.31 | $1.87 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 11.36 | 11.25 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.